Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 20,492 | $82.70 | $1,694,688.40 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 6 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,885 F2 · price: This transaction was executed in multiple trades at prices ranging from 82.53 to 82.87. The price reported above represents the weighted average sales price. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 11,815 | $82.71 | $977,218.65 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 5 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,377 F1 · price: This transaction was executed in multiple trades at prices ranging from 82.51 to 82.88. The price reported above represents the weighted average sales price. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 82,460 | $27.58 | $2,274,246.80 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 3,625 | $27.58 | $99,977.50 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,492 | $58.24 | $1,193,454.08 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 11,815 | $52.02 | $614,616.30 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 21:28 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-041597 · doc1.xml · derivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 21:28 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $83.82 | $167,634.00 |
DisclosureSEC source: 0001140361-17-041597 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,800 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $83.76 to $83.93. The price reported above reflects the weighted average sale price. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 21:28 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 18,000 | $83.50 | $1,502,946.00 |
DisclosureSEC source: 0001140361-17-041597 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,800 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 82.75 to 83.75. The price reported above represents the weighted average sales price. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 21:28 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-041597 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 03, 2017 Filed Nov 6, 2017 19:47 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,364 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-041119 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 6,364 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| November 03, 2017 Filed Nov 6, 2017 19:47 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,364 | $82.20 | $523,120.80 |
DisclosureSEC source: 0001140361-17-041119 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,384 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $82.09 to $82.24. The price reported above reflects the weighted average sale price. F3 · balance_after: Includes 180.77 shares of ResMed stock purchased on 10/31/2017, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 03, 2017 Filed Nov 6, 2017 19:47 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,364 | $27.58 | $175,519.12 |
DisclosureSEC source: 0001140361-17-041119 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · balance_after: Includes 180.77 shares of ResMed stock purchased on 10/31/2017, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 23:12 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,250 | $84.50 | $105,625.00 |
DisclosureSEC source: 0001140361-17-040829 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,772 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| October 31, 2017 Filed Nov 1, 2017 23:50 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,300 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-040605 · doc1.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 3,300 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction represents an exercise and hold of expiring options. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| October 31, 2017 Filed Nov 1, 2017 23:50 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 3,300 | $33.70 | $111,210.00 |
DisclosureSEC source: 0001140361-17-040605 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction represents an exercise and hold of expiring options. F2 · shares: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 20:26 UTC |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 2,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038532 · doc1.xml · nonDerivative · entry 2 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,008 F2 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 20:26 UTC |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 2,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038532 · doc1.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,059 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 20:18 UTC |
McHale RichardPresident, RC Business
|
GrantResMed Common Stock | 1,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038528 · doc1.xml · nonDerivative · entry 2 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,520 F2 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 20:18 UTC |
McHale RichardPresident, RC Business
|
GrantResMed Common Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038528 · doc1.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,554 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 19:47 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 4,301 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038521 · doc1.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,022 F2 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 19:47 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 4,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038521 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,721 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 19:40 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 9,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038520 · doc1.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,600 F2 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 19:40 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 8,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038520 · doc1.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,769 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 19:31 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 14,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038519 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,432 F2 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 19:31 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 12,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038519 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,686 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 19:19 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 3,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038518 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,203 F2 · kind: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 19:19 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 3,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038518 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,271 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 19:17 UTC |
Hollingshead JamesPresident, Americas
|
GrantResMed Common Stock | 3,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038516 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,471 F2 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 19:17 UTC |
Hollingshead JamesPresident, Americas
|
GrantResMed Common Stock | 3,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038516 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,539 F1 · shares: Represents performance-based restricted stock units granted on November 19, 2015. The shares were earned on October 10, 2017, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 16:54 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-037762 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 16:54 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 20,000 | $77.01 | $1,540,200.00 |
DisclosureSEC source: 0001140361-17-037762 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,800 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 76.38 to 77.34. The price reported above represents the weighted average sales price. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 16:54 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-037762 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 16:49 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,364 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-037704 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,364 Underlying: ResMed Common Stock · 6,364 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 16:49 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,364 | $76.94 | $489,646.16 |
DisclosureSEC source: 0001140361-17-037704 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,808 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.88 to $77.32. The price reported above reflects the weighted average sale price. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 16:49 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,364 | $27.58 | $175,519.12 |
DisclosureSEC source: 0001140361-17-037704 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 21:54 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,250 | $77.05 | $96,312.50 |
DisclosureSEC source: 0001140361-17-037427 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,691 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 16:42 UTC |
ROBERTS CHRISTOPHER GDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 25,934 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001140361-17-037277 · doc1.xml · derivative · entry 5 ROBERTS CHRISTOPHER G · CIK 0001186112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 25,934 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction to exercise options and hold shares acquired through purchase. F2 · derivative.exercise_date: Options vest in full on (i) the first November 11 following the grant date, or (ii) the first annual shareholder's meeting following grant date. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 16:42 UTC |
ROBERTS CHRISTOPHER GDirector
|
Exercise / conversionResMed Common Stock | 25,934 | $38.98 | $1,010,907.32 |
DisclosureSEC source: 0001140361-17-037277 · doc1.xml · nonDerivative · entry 1 ROBERTS CHRISTOPHER G · CIK 0001186112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction to exercise options and hold shares acquired through purchase. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:55 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-034452 · doc1.xml · derivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:55 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 1,122 | $77.41 | $86,854.02 |
DisclosureSEC source: 0001140361-17-034452 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,800 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from 77.38 to 77.45. The price reported above represents the weighted average sales price. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:55 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 18,878 | $76.70 | $1,447,942.60 |
DisclosureSEC source: 0001140361-17-034452 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,922 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 76.38 to 77.37. The price reported above represents the weighted average sales price. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:55 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-034452 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 20:13 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,364 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-034431 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,728 Underlying: ResMed Common Stock · 6,364 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 20:13 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,364 | $77.21 | $491,364.44 |
DisclosureSEC source: 0001140361-17-034431 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,808 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.08 to $77.40. The price reported above reflects the weighted average sale price. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 20:13 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,364 | $27.58 | $175,519.12 |
DisclosureSEC source: 0001140361-17-034431 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 15:45 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,250 | $77.56 | $96,950.00 |
DisclosureSEC source: 0001140361-17-034230 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,941 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 6,757 | $74.17 | $501,166.69 |
DisclosureSEC source: 0001140361-17-033105 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,800 F1 · kind: Represents a gift to the Scripps Research Institute, a 501(c)(3) non-profit corporation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F1 · shares: Represents a gift to the Scripps Research Institute, a 501(c)(3) non-profit corporation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F2 · price: This transaction was executed in multiple trades at prices ranging from 73.49 to 74.85. The price reported above represents the weighted average sales price. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 15:23 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 7,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-032790 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,191 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on August 17, 2017, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 15:21 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 1,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-032789 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,808 F2 · shares: Represents performance-based restricted stock units granted on June 1, 2017. The shares were earned on August 17, 2017, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.